Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Oregon: below-average open trial sites
679 of 1,999 in-state trials are recruiting (34%); below the 37% national average by 3 percentage points.
According to ClinicalTrials.gov-derived indexes, Oregon sits in the lower half of US states by in-state trial count (#28 of 52 states by registered in-state trial count).
Oregon: 1,999 US clinical trials with in-state sites, 679 recruiting.
Oregon has 1,999 registered US clinical trials with a study site in-state, 679 of them currently recruiting (below the 37% national average by 3 percentage points). 354 of these trials are in Phase 3 (late-stage) and 493 in Phase 2. The most frequently studied condition in Oregon is Non-Small Cell Lung Cancer, with 38 linked trials.
Lower-half Oregon archive
Oregon's in-state trials target 16,843 patients on average (p94 by trial size among 52 states with enrollment data), larger, multi-site studies than most states. Treat this page as a compact local index (mid-volume · high-open), then jump to recruiting trials or methodology rather than expecting hub-scale coverage.
Below-average open enrollment
Oregon still shows 679 recruiting of 1,999 in-state trials (34% open), but below the 37% national average by 3 percentage points, so archived statuses weigh heavier than the national baseline.
- 34%
- open (below national share)
- 679
- still recruiting despite cool share
- 493
- Phase 2 rows in this footprint
- 38
- top: Non-Small Cell Lung Cancer
Recruiting share is below the 37% national average by 3 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Oregon vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
1,999 Top 54% more indexed trials than 46% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for Oregon on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Oregon open-enrollment share sits below the national baseline.
679 of 1,999 in-state trials (34%) are recruiting, against 37% nationally (-3 percentage points). Counts include every study with at least one recorded site in the state.
-
Portland dominates Oregon's trial geography.
Portland lists 1,620 of 1,999 in-state trials (81%) across 511 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Non-Small Cell Lung Cancer is the most-studied condition in Oregon.
38 of 1,999 in-state trials (1.9%) list Non-Small Cell Lung Cancer. That is a local concentration figure, not a national disease ranking.
-
Oregon sponsorship is fragmented across many organizations.
Oregon Health and Science University appears on 177 of 1,999 in-state trials (8.9%). Sponsor identity is as filed on ClinicalTrials.gov.
-
844 Oregon trials carry a completed status.
844 of 1,999 (42.2%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 844 |
| Recruiting | 679 |
| Active | 476 |
By Phase
| Phase | Trial count |
|---|---|
| Phase 2 | 493 |
| NA | 420 |
| Phase 1 | 367 |
| Phase 3 | 354 |
| Phase 4 | 84 |
| Early Phase 1 | 21 |
Top Conditions
Top Sponsors
Where trials run in Oregon
Portland carries 1,620 of Oregon's 1,999 indexed trials (81%) across 511 named sites, ahead of Eugene at 199. 8 cities clear five listed trials, together naming 729 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Portland | 1,620 | 511 |
| Eugene | 199 | 106 |
| Medford | 72 | 37 |
| Springfield | 36 | 19 |
| Corvallis | 32 | 17 |
| Bend | 26 | 21 |
| Salem | 13 | 9 |
| Tigard | 11 | 9 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Trial size large
Oregon's in-state trials target 16,843 patients on average (p94 by trial size among 52 states with enrollment data), larger, multi-site studies than most states.
Oregon: in-state trial volume sits mid-pack
Geography is concentrated: Portland alone accounts for 81% of Oregon's indexed trials (1,620 of 1,999), with Eugene a distant second at 199.
Phase mix: 354 Phase 3 vs 493 Phase 2 (balanced across stages).
Top condition: Non-Small Cell Lung Cancer (38 trials); top sponsor Oregon Health and Science University (177).
mid-volume · high-open figures (1,999 trials · 34% open) describe registry geography under the trial size large read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near Oregon on in-state trial volume
Cross-state peers under the trial size large read (mid-volume · high-open), not the same-state browse list.
Similar mid-volume peers (± open share)
Similar high-open peers (± trial volume)
- Maryland · 34% recruiting · 6,441 trials
- Pennsylvania · 34% recruiting · 6,946 trials
- Rhode Island · 34% recruiting · 753 trials
- New Jersey · 34% recruiting · 3,402 trials
- Oklahoma · 34% recruiting · 1,061 trials